Esperion Therapeutics, Inc.
The research page contains a warning that has not been mapped to a supported model interpretation. The company research remains available, but the complete score is withheld until the warning is reviewed.
ESPR · Price history
Company & revenue
About Esperion Therapeutics, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Esperion Therapeutics, Inc. operates as a pharmaceutical firm, concentrating on the development and commercialization of treatments for individuals with high levels of low-density lipoprotein (LDL) cholesterol. The company's flagship pharmaceutical products are NEXLETOL (bempedoic acid) and NEXLIZET (a tablet combining bempedoic acid and ezetimibe), prescribed for managing conditions such as atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. In addition, Esperion maintains a licensing and collaborative partnership with Daiichi Sankyo Europe GmbH, alongside an agreement with Serometrix to acquire rights to an oral, small molecule PCSK9 inhibitor program.
How they make money
Esperion Therapeutics is a commercial-stage biopharmaceutical company that generates revenue primarily through the sale of its bempedoic acid-based products, NEXLETOL and NEXLIZET, in the United States. The company also earns revenue through royalty payments from international commercial partners who market and sell these products in their respective territories, as well as through collaboration and license agreements.
Products & services
The company markets NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets, which are non-statin, oral, once-daily medicines used to lower low-density lipoprotein cholesterol (LDL-C) in patients with cardiovascular disease or those at risk of cardiovascular events.
Brands & revenue mix
Oral, once-daily non-statin cholesterol-lowering medication.
Separate brand revenue is not available in this research.Source
Combination therapy of bempedoic acid and ezetimibe for cholesterol management.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer concentration
The company's product sales are primarily distributed through a network of wholesale distributors and specialty pharmacies in the United States, with revenue concentration typical of the pharmaceutical industry.
Suppliers, materials & equipment
- Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its active pharmaceutical ingredients and finished drug products; specific supplier names are not disclosed.Source
Business relationships & partnerships
- HLS Therapeutics — Commercial partner for the marketing and distribution of NEXLETOL and NEXLIZET in Canada.Source
Strengths
Company-specific research
Questions worth answering for ESPR
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can ESPR maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •How long can ESPR fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •Is ESPR's debt load manageable relative to cash generation, interest costs and upcoming maturities?
- •What specifically needs to improve for ESPR to reach sustainable profitability?
- •What future growth or profitability would be needed to justify ESPR's current valuation?
Essential Investment Snapshot
Market Cap
$661.1M
P/E Ratio
-131.4
EPS
$-0.02
52-Week High
$4.17
52-Week Low
$1.13
Beta
1.06
Analyst Target
$3.16
Shares Outstanding
207.9M
Total Debt
$543.8M
Dividend
No current dividend
Liquidation Value / Share
$-1.48
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Notices for ESPR
Detected from reported data — verify before acting.Severe debt stress
Negative shareholder equity • Total debt is at least one year of revenue • Interest coverage is below 2x • Free cash flow is negative
Community Sentiment
0 active · 0 total callsNo personal call yet on ESPR.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Strong commercial momentum for bempedoic acid franchise.
- +Broad payer coverage exceeding 90% of commercial and Medicare lives.
Potential downside factors
- −Debt risk (severe): Negative shareholder equity.
- −Total debt is at least one year of revenue.
- −Interest coverage is below 2x.
- −Free cash flow is negative.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
Score changes will appear once more historical records are available.
Price vs. Value
Valuation unavailableCurrent Price
$3.18
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $418.2M | $403.1M | $332.3M | $116.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $146.4M | $129.2M | $68.6M | $43.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $271.9M | $273.9M | $263.7M | $73.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $44.3M | $47.9M | $46.2M | $86.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $165.9M | $165.8M | $163.1M | $142.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $196.1M | $213.6M | $209.3M | $228.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | $39.9M | $63.9M | $7.6M | -$150.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | $75.8M | $60.3M | $54.4M | -$155.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $45.4M | $84.6M | $59.3M | $59.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$5.6M | -$20.8M | -$51.7M | -$209.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $1.8M | $1.8M | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$7.4M | -$22.7M | -$51.7M | -$209.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-0.02 | $-0.11 | $-0.28 | $-2.03 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 251M | 208M | 187M | 103M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 251M | 208M | 187M | 103M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$80.1M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.10
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
+82.6%
Cash Change
+36.2%
Margin Change
+30.8 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Margins expanded
- Cash position grew
What Weakened
- Debt increased
Potential Score Impact
Positive indicators included revenue growth, cash levels, net income margin. Pressure indicators included EPS growth, debt levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 23.2%. EPS declined 52.4%. Cash increased 36.2%. Total debt increased 82.6%. Net income margin improved by 30.8 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
6 historical recordsHistorical Score Chart
3 of 6 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
No news available for ESPR.
Rumor Mill · ESPR
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial